The Energetic Cost of Adrenergic Signaling in Primary Human Fibroblasts

Technical Summary: The Energetic Cost of Adrenergic Signaling in Primary Human Fibroblasts

Problem Statement
While the systemic metabolic effects of the stress response—specifically the release of norepinephrine (NE) via the sympathetic-adreno-medullar (SAM) axis—are well characterized at the organismal level, the cell-autonomous bioenergetic consequences of adrenergic signaling remain poorly understood. Specifically, the mechanisms by which NE causes individual cells to recalibrate their energy-transforming pathways (oxidative phosphorylation vs. glycolysis) and the temporal dynamics of this energetic cost have not been resolved. Furthermore, it is unclear how genetic defects in mitochondrial function, such as those found in mitochondrial diseases, alter the cellular capacity to meet the energetic demands imposed by adrenergic signaling.

Methodology
The study utilized primary human fibroblasts, a model system known to express adrenergic receptor subtypes, to quantify the dose- and time-dependent effects of NE stimulation.

• Experimental Design: Cells were stimulated with NE concentrations ranging from 0 to 10 µM. Metabolic flux was monitored continuously for up to 10 hours using extracellular flux analysis (Seahorse XF).
• Measurements: Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) were measured at ~6-minute intervals. These metrics were used to estimate ATP turnover rates derived from oxidative phosphorylation (OxPhos) and glycolysis, respectively, using a pseudo-ATP calculation framework adapted from Desousa et al.
• Conditions:
  • Dose-Response: Eight doses of NE were tested to establish concentration dependence.
  • Metabolic Flexibility: To probe pathway reliance, cells were subjected to glucose depletion (24 hours) or pharmacological inhibition of OxPhos using oligomycin (Complex V inhibitor) and piericidin A (Complex I inhibitor).
  • Genetic Deficiency: Patient-derived fibroblasts harboring SURF1 mutations (impairing Complex IV assembly and reducing OxPhos capacity) were compared against healthy controls to assess the impact of mitochondrial dysfunction on the adrenergic response.
• Data Analysis: ATP production rates were calculated from baseline-corrected OCR and ECAR. Statistical significance was determined using linear mixed-effects models with Bonferroni correction.

Key Results

1. Temporal Dynamics of Adrenergic Signaling: NE stimulation induces a biphasic energetic response.

   • Early Phase (0–18 minutes): There is a rapid, dose-dependent increase in glycolysis (ECAR), peaking at a 47% increase at 10 µM NE. Concurrently, respiration (OCR) decreases slightly (2–5%).
   • Mid-to-Late Phase (2–6 hours): Following the initial glycolytic spike, OxPhos increases, peaking at 9–12% above baseline.
   • Total Energy Expenditure: Total ATP production increases in a dose- and time-dependent manner, reaching up to ~15% above control levels at 10 µM NE.

2. Metabolic Flexibility and Substrate Availability:

   • In the presence of glucose, the early rise in energy expenditure is predominantly driven by glycolysis (accounting for ~95% of the total increase).
   • When glucose is depleted, cells demonstrate metabolic flexibility by redirecting the NE-stimulated ATP production to OxPhos, which accounts for ~71.8% of the total increase.
   • Pharmacological inhibition of OxPhos forces the cells to rely entirely on glycolysis to meet the energetic demand, resulting in an even larger relative increase in glycolytic ATP production compared to controls.

3. Impact of Mitochondrial Deficiency (SURF1 Mutants):

   • SURF1-mutant cells exhibit a hypermetabolic baseline, with total energy expenditure 11.4% higher than healthy controls, driven by a compensatory 83.3% increase in glycolytic ATP production.
   • Upon NE stimulation, these mutant cells mount a significantly blunted response. While healthy controls increased total ATP production by ~95% at 1 µM NE, SURF1 mutants increased by only ~50%.
   • The glycolytic response in mutants was approximately 50% lower than in healthy controls. Additionally, SURF1 mutants showed a 54.3% reduction in the expression of the highly expressed AR-α2A receptor subtype compared to controls.

Significance and Claims
The authors claim to have resolved the temporal dynamics and flexible bioenergetic recalibrations associated with NE-driven hypermetabolism in primary human fibroblasts. The study establishes that adrenergic signaling is an energetically demanding process that operates upstream of specific metabolic pathway selection, with the utilized pathway (glycolysis vs. OxPhos) determined by substrate availability and enzymatic capacity.

Crucially, the paper posits that the blunted response in SURF1-mutant cells provides insight into mitochondrial disease physiology. The data suggest that cells with compromised mitochondria generate a smaller absolute increase in ATP per unit of adrenergic signal. Consequently, achieving a comparable energetic response in these cells would require greater sympathetic stimulation. This finding supports the concept of "energy constraints" in mitochondrial diseases, where the inability to scale energy production efficiently may underlie pathophysiology. The authors conclude that mapping these recalibrations in humans could advance the understanding of the energetic forces underlying health damage caused by chronic stress.